Global Pain Therapeutics Market size was valued at USD 58,116.3 million in 2018 to USD 74,483.8 million in 2024 and is anticipated to reach USD 1,10,568.4 million by 2032, at a CAGR of 5.12% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Pain Therapeutics Market Size 2024
USD 74,483.8 Million
Pain Therapeutics Market, CAGR
5.12%
Pain Therapeutics Market Size 2032
USD 1,10,568.4 Million
The Global Pain Therapeutics Market is driven by major players including Abbott, Pfizer Inc., AstraZeneca plc, Boston Scientific Corporation, Bristol-Myers Squibb and Company, Eli Lilly and Company, GSK plc, Merck & Co. Inc., Purdue Pharma L.P., and Sanofi S.A., alongside several regional and generic manufacturers. These companies maintain leadership through broad drug portfolios, strong R&D pipelines, and strategic collaborations aimed at expanding non-opioid and personalized therapies. Among regions, Asia Pacific emerged as the leader in 2024 with a 35.9% market share, supported by rapid healthcare expansion, a large patient base, and growing demand for modern pain management solutions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Global Pain Therapeutics Market grew from USD 58,116.3 million in 2018 to USD 74,483.8 million in 2024, and is projected to reach USD 1,10,568.4 million by 2032.
Opioid analgesics dominated with 41% share in 2024, while non-opioids including NSAIDs (21%) and acetaminophen (11%) gained traction as safer alternatives.
Nociceptive pain led applications with 52% share in 2024, followed by neuropathic pain at 34% and psychogenic pain at 14%.
Hospital pharmacies accounted for 49% of distribution in 2024, with retail pharmacies at 37% and others, including online platforms, contributing 14%.
Asia Pacific led the market with 35.9% share in 2024, followed by Europe at 29.4% and North America at 19.3%, reflecting strong global demand.
Market Segment Insights
By Drug Class
The Global Pain Therapeutics Market by drug class is led by opioid analgesics, holding a 41% share in 2024. Their dominance stems from widespread use in treating moderate to severe chronic pain, particularly in oncology and post-surgical care. Non-opioid analgesics account for a 32% share, with NSAIDs contributing 21% and acetaminophen 11%, driven by rising demand for safer alternatives to opioids. Antidepressants capture 15% of the market, supported by their expanding use in neuropathic pain management. Other drug classes represent the remaining 12%, reflecting niche but growing applications in targeted therapies.
For instance, in April 2024, Pfizer and Acura Pharmaceuticals announced FDA approval of OXECTA, an immediate-release oxycodone tablets with tamper-deterrent technology, indicated for acute and chronic moderate to severe pain.
By Application
In application segmentation, nociceptive pain dominates with a 52% share in 2024, supported by the high prevalence of musculoskeletal disorders, arthritis, and injury-related conditions. Neuropathic pain holds a 34% share, propelled by increasing cases of diabetic neuropathy, multiple sclerosis, and chemotherapy-induced pain. Psychogenic pain accounts for 14%, with gradual growth as awareness rises regarding psychosomatic conditions and the integration of mental health into pain management strategies.
For instance, Kaia Health’s digital therapeutics app, combining cognitive-behavioral therapy (CBT) and AI-driven coaching, showed effectiveness in managing chronic pain including psychogenic types, highlighting mental health’s role in pain relief.
By Distribution Channel
The market by distribution channel is led by hospital pharmacies, which hold a 49% share in 2024 due to the strong reliance on hospital settings for post-operative pain care and chronic disease management. Retail pharmacies follow with a 37% share, driven by easy access to prescription and OTC drugs for self-management of pain. The others category, including online pharmacies and specialty clinics, contributes 14%, reflecting steady growth fueled by digital health adoption and patient preference for home delivery of medications.
Key Growth Drivers
Rising Prevalence of Chronic Pain Disorders
The rising burden of chronic conditions such as arthritis, cancer, and lower back pain significantly drives demand for pain therapeutics. An aging global population further intensifies the need for long-term pain management solutions. Growing awareness of early treatment options has accelerated the uptake of both opioid and non-opioid drugs. This trend positions chronic pain therapies as a critical growth driver, strengthening the overall market outlook.
For instance, Eli Lilly launched its injectable therapy Zepbound (tirzepatide) for obesity and related conditions, and clinical studies reported secondary benefits in pain and mobility improvements among patients with severe joint stress.
Expansion of Non-Opioid Therapeutics
Increasing concerns regarding opioid dependence and stringent prescribing guidelines have fueled the demand for non-opioid alternatives. NSAIDs, acetaminophen, and antidepressants are gaining strong adoption as safer long-term options. Pharmaceutical innovation focusing on novel non-addictive drugs continues to expand the therapeutic landscape. This shift is reshaping prescribing patterns and driving revenue growth across non-opioid drug classes.
For instance,Vertex Pharmaceuticals reported Phase 2 trial success for VX-548, a novel oral NaV1.8 inhibitor for acute pain, showing opioid-level efficacy without dependence risk.
Advances in Personalized and Targeted Therapy
Technological progress in pharmacogenomics and biomarker-based research supports the development of targeted pain therapeutics. These innovations allow more precise treatment strategies tailored to individual patient needs. Such approaches reduce side effects while improving therapeutic outcomes. The emphasis on personalized medicine is encouraging R&D investments and opening new revenue streams in the global market.
Key Trends & Opportunities
Integration of Digital Health and Remote Monitoring
The growing use of telemedicine and digital health platforms offers new opportunities for pain management. Remote monitoring tools enhance medication adherence and improve real-time treatment adjustments. Digital health adoption is accelerating in developed markets and gradually expanding into emerging economies. This trend enhances patient engagement while creating new partnerships between pharmaceutical companies and digital health providers.
For instance, Sword Health uses AI-powered virtual physical therapy for musculoskeletal pain. Their programs reduced surgery rates by about 50 % and saved customers roughly US $3,177 per member annually.
Expansion in Emerging Markets
Rising healthcare expenditure and growing access to modern therapies in Asia-Pacific, Latin America, and the Middle East create strong opportunities. Increasing investment in healthcare infrastructure and supportive regulatory reforms are enabling faster drug approvals. A large patient pool and rising awareness about pain therapies further strengthen growth potential in these regions. Market players are increasingly expanding their distribution networks and R&D collaborations to capture these opportunities.
For instance, China’s NMPA approved 55 rare disease drugs in 2024, enabled by regulatory reforms aiming to speed up approvals.
Key Challenges
Opioid Misuse and Regulatory Restrictions
The global opioid crisis has led to strict regulations and heightened scrutiny of prescribing practices. These measures restrict access to opioid-based pain relief, limiting revenue growth for this major segment. Pharmaceutical companies face challenges balancing effective pain management with compliance requirements. The need for stricter monitoring adds complexity for healthcare providers.
High Risk of Side Effects
Many pain therapeutics, including NSAIDs and antidepressants, carry significant side-effect risks such as gastrointestinal bleeding, cardiovascular complications, or dependency issues. These risks reduce patient adherence and create hesitation among prescribers. Developing safer drug formulations is costly and time-consuming, slowing the pace of innovation. Managing adverse effects remains a persistent challenge for the industry.
Pricing Pressure and Generic Competition
The presence of numerous generics exerts downward pressure on pricing across major drug classes. Patent expirations of blockbuster pain medications intensify competition and limit profit margins for established players. Payers and governments increasingly demand cost-effective treatment options, forcing companies to justify pricing. These pressures constrain revenue growth and affect long-term investment in new therapies.
Regional Analysis
North America
North America accounted for 19.3% of the global market in 2024, supported by advanced healthcare infrastructure and strong adoption of pain therapeutics. Market size grew from USD 11,495.41 million in 2018 to USD 14,378.57 million in 2024 and is projected to reach USD 20,643.12 million by 2032, expanding at a CAGR of 4.7%. The region benefits from high prevalence of chronic pain disorders and strong insurance coverage. Regulatory reforms and rising demand for non-opioid therapies further support steady growth, though opioid regulations continue to shape treatment patterns.
Europe
Europe held 29.4% of the market share in 2024, making it one of the largest contributors to global revenue. Market value increased from USD 17,388.41 million in 2018 to USD 21,915.27 million in 2024, with forecasts reaching USD 31,799.47 million by 2032 at a CAGR of 4.8%. The region’s growth is driven by robust government healthcare systems, high patient awareness, and extensive use of both opioid and non-opioid therapeutics. Stringent regulations and the strong presence of multinational pharmaceutical companies continue to reinforce Europe’s leadership in this market.
Asia Pacific
Asia Pacific emerged as the largest regional market with 35.9% share in 2024, supported by rapid urbanization and growing healthcare spending. Market size expanded from USD 20,921.88 million in 2018 to USD 26,782.26 million in 2024, and is expected to reach USD 39,694.05 million by 2032 at a CAGR of 5.1%. The region benefits from a large patient pool, rising cases of lifestyle-related pain disorders, and increasing access to modern therapies. Pharmaceutical companies are actively expanding their footprint in China, India, and Japan, fueling further growth potential.
Latin America
Latin America represented 7.4% of the global market in 2024, showing strong growth potential compared with developed regions. The market grew from USD 4,010.03 million in 2018 to USD 5,490.52 million in 2024, and is projected to reach USD 8,845.47 million by 2032, advancing at a CAGR of 6.2%. Growth is driven by improving healthcare access, increasing awareness of chronic pain management, and rising investments in hospital infrastructure. Brazil and Argentina remain the largest contributors, while the expansion of retail pharmacies supports broader availability of pain therapeutics.
Middle East
The Middle East accounted for 5.3% of market share in 2024, with the sector gaining momentum due to rising healthcare investments. Market size expanded from USD 2,777.96 million in 2018 to USD 3,914.66 million in 2024, and is forecasted to reach USD 6,512.48 million by 2032, at a CAGR of 6.6%. Countries in the GCC lead adoption, driven by better infrastructure and rising burden of lifestyle diseases. Government-backed initiatives to modernize healthcare systems are creating new opportunities for pharmaceutical companies in pain management.
Africa
Africa contributed 2.7% to the global market in 2024, reflecting its position as an emerging but smaller segment. Market size grew from USD 1,522.65 million in 2018 to USD 2,002.55 million in 2024, and is projected to reach USD 3,073.80 million by 2032 at a CAGR of 5.6%. Rising prevalence of untreated chronic pain, coupled with increasing healthcare investments in South Africa, Egypt, and Nigeria, drives gradual adoption of pain therapeutics. Limited access to advanced drugs remains a challenge, though expanding distribution channels are expected to improve penetration over time.
Market Segmentations:
By Drug Class
Opioid Analgesics
Non-Opioid Analgesics
NSAIDs
Acetaminophen
Antidepressants
Others
By Application
Nociceptive Pain
Neuropathic Pain
Psychogenic Pai
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The Global Pain Therapeutics Market is highly competitive, with both multinational pharmaceutical giants and regional players shaping its dynamics. Leading companies such as Abbott, Pfizer, AstraZeneca, Eli Lilly, GSK, Merck & Co., Bristol-Myers Squibb, and Sanofi dominate through extensive portfolios covering opioid and non-opioid therapies. Their strong R&D investments, broad distribution networks, and strategic collaborations secure significant market positions. Purdue Pharma and Boston Scientific contribute with specialized pain management solutions, while emerging firms and generic manufacturers increase competition by offering cost-effective alternatives. Market leaders focus on developing safer non-opioid drugs, personalized therapies, and extended-release formulations to address regulatory pressures and concerns over opioid misuse. Competitive intensity is further heightened by patent expirations, which have enabled generic penetration across major drug classes. Companies are responding with innovation, lifecycle management strategies, and expansion into high-growth regions such as Asia-Pacific and Latin.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In January 2025, Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a first-in-class non-opioid therapy for adults with moderate-to-severe acute pain.
In May 2025, Eli Lilly announced the acquisition of SiteOne Therapeutics to expand its non-opioid pain pipeline with the investigational Nav1.8 inhibitor STC-004.
In August 2025, Tonix Pharmaceuticals secured FDA approval for Tonmya (cyclobenzaprine HCl sublingual), the first new fibromyalgia treatment in over 15 years.
Report Coverage
The research report offers an in-depth analysis based on Drug Class, Application, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for non-opioid pain therapeutics will continue to expand across all major regions.
Rising geriatric population will drive long-term demand for chronic pain management solutions.
Innovation in personalized and targeted therapies will improve treatment effectiveness and safety.
Digital health integration will enhance patient monitoring and adherence in pain management.
Emerging markets will gain importance as healthcare access and awareness levels improve.
Pharmaceutical companies will focus on lifecycle management and extended-release formulations.
Regulatory pressure on opioid prescriptions will strengthen adoption of alternative therapies.
Growing prevalence of lifestyle-related disorders will create new opportunities for pain therapeutics.
Strategic collaborations between pharma and biotech firms will accelerate new drug development.
Expansion of distribution channels, including online pharmacies, will improve global drug accessibility.
CHAPTER NO. 1 : GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2 : EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3 : PAIN THERAPEUTICS MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
CHAPTER NO. 4 : KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Drug Class Frontiers – Lucrative Drug Class Categories
4.3 Distribution Channel Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Drug Class, Application, and Distribution Channel Revenue CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS
6.1. Import Analysis By Region
6.1.1. Global Pain Therapeutics Market Import Revenue By Region
6.2. Export Analysis By Region
6.2.1. Global Pain Therapeutics Market Export Revenue By Region CHAPTER NO. 7 : COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Pain Therapeutics Market: Company Market Share
7.2. Global Pain Therapeutics Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Drug Class Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8 : PAIN THERAPEUTICS MARKET – BY DRUG CLASS SEGMENT ANALYSIS
8.1. Pain Therapeutics Market Overview By Drug Class Segment
8.1.1. Pain Therapeutics Market Revenue Share By Drug Class
8.2. Opioid Analgesics
8.3. Non-Opioid Analgesics
8.3.1. NSAIDs
8.3.2. Acetaminophen
8.4. Antidepressants
8.5. Antidepressants
8.6. Others CHAPTER NO. 9 : PAIN THERAPEUTICS MARKET – BY APPLICATION SEGMENT ANALYSIS
9.1. Pain Therapeutics Market Overview By Application Segment
9.1.1. Pain Therapeutics Market Revenue Share By Application
9.2. Nociceptive Pain
9.3. Neuropathic Pain
9.4. Psychogenic Pain CHAPTER NO. 10 : PAIN THERAPEUTICS MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS
10.1. Pain Therapeutics Market Overview By Distribution Channel Segment
10.1.1. Pain Therapeutics Market Revenue Share By Distribution Channel
10.2. Hospitals Pharmacies
10.3. Retail Pharmacies
10.4. Others CHAPTER NO. 11 : PAIN THERAPEUTICS MARKET – REGIONAL ANALYSIS
11.1. Pain Therapeutics Market Overview By Region Segment
11.1.1. Global Pain Therapeutics Market Revenue Share By Region
10.1.2. Regions
11.1.3. Global Pain Therapeutics Market Revenue By Region
11.1.4. Drug Class
11.1.5. Global Pain Therapeutics Market Revenue By Drug Class
11.1.6. Application
11.1.7. Global Pain Therapeutics Market Revenue By Application
11.1.8. Distribution Channel
11.1.9. Global Pain Therapeutics Market Revenue By Distribution Channel CHAPTER NO. 12 : NORTH AMERICA PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
12.1. North America Pain Therapeutics Market Overview By Country Segment
12.1.1. North America Pain Therapeutics Market Revenue Share By Region
12.2. North America
12.2.1. North America Pain Therapeutics Market Revenue By Country
12.2.2. Drug Class
12.2.3. North America Pain Therapeutics Market Revenue By Drug Class
12.2.4. Application
12.2.5. North America Pain Therapeutics Market Revenue By Application
12.2.6. Distribution Channel
12.2.7. North America Pain Therapeutics Market Revenue By Distribution Channel
12.3. U.S.
12.4. Canada
12.5. Mexico CHAPTER NO. 13 : EUROPE PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
13.1. Europe Pain Therapeutics Market Overview By Country Segment
13.1.1. Europe Pain Therapeutics Market Revenue Share By Region
13.2. Europe
13.2.1. Europe Pain Therapeutics Market Revenue By Country
13.2.2. Drug Class
13.2.3. Europe Pain Therapeutics Market Revenue By Drug Class
13.2.4. Application
13.2.5. Europe Pain Therapeutics Market Revenue By Application
13.2.6. Distribution Channel
13.2.7. Europe Pain Therapeutics Market Revenue By Distribution Channel
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe CHAPTER NO. 14 : ASIA PACIFIC PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Pain Therapeutics Market Overview By Country Segment
14.1.1. Asia Pacific Pain Therapeutics Market Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Pain Therapeutics Market Revenue By Country
14.2.2. Drug Class
14.2.3. Asia Pacific Pain Therapeutics Market Revenue By Drug Class
14.2.4. Application
14.2.5. Asia Pacific Pain Therapeutics Market Revenue By Application
14.2.6. Distribution Channel
14.2.7. Asia Pacific Pain Therapeutics Market Revenue By Distribution Channel
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific CHAPTER NO. 15 : LATIN AMERICA PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
15.1. Latin America Pain Therapeutics Market Overview By Country Segment
15.1.1. Latin America Pain Therapeutics Market Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Pain Therapeutics Market Revenue By Country
15.2.2. Drug Class
15.2.3. Latin America Pain Therapeutics Market Revenue By Drug Class
15.2.4. Application
15.2.5. Latin America Pain Therapeutics Market Revenue By Application
15.2.6. Distribution Channel
15.2.7. Latin America Pain Therapeutics Market Revenue By Distribution Channel
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America CHAPTER NO. 16 : MIDDLE EAST PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
16.1. Middle East Pain Therapeutics Market Overview By Country Segment
16.1.1. Middle East Pain Therapeutics Market Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Pain Therapeutics Market Revenue By Country
16.2.2. Drug Class
16.2.3. Middle East Pain Therapeutics Market Revenue By Drug Class
16.2.4. Application
16.2.5. Middle East Pain Therapeutics Market Revenue By Application
16.2.6. Distribution Channel
16.2.7. Middle East Pain Therapeutics Market Revenue By Distribution Channel
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East CHAPTER NO. 17 : AFRICA PAIN THERAPEUTICS MARKET – COUNTRY ANALYSIS
17.1. Africa Pain Therapeutics Market Overview By Country Segment
17.1.1. Africa Pain Therapeutics Market Revenue Share By Region
17.2. Africa
17.2.1. Africa Pain Therapeutics Market Revenue By Country
17.2.2. Drug Class
17.2.3. Africa Pain Therapeutics Market Revenue By Drug Class
17.2.4. Application
17.2.5. Africa Pain Therapeutics Market Revenue By Application
17.2.6. Distribution Channel
17.2.7. Africa Pain Therapeutics Market Revenue By Distribution Channel
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa CHAPTER NO. 18 : COMPANY PROFILES
18.1. Abbott
18.1.1. Company Overview
18.1.2. Drug Class Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. Pfizer Inc.
18.3. AstraZeneca plc
18.4. Boston Scientific Corporation
18.5. Bristol-Myers Squibb and Company
18.6. Eli Lily and Company
18.7. GSK plc
18.8. Merck & Co. Inc.
18.9. Purdue Pharma L.P.
18.10. Sanofi S.A.
18.11. Other Key Players
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Global Pain Therapeutics Market, and what is its projected size in 2032?
The Global Pain Therapeutics Market size reached USD 74,483.8 million in 2024 and is projected to achieve USD 1,10,568.4 million by 2032, indicating strong long-term growth.
At what Compound Annual Growth Rate is the Global Pain Therapeutics Market projected to grow between 2025 and 2032?
The Global Pain Therapeutics Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.12% during the forecast period spanning from 2025 to 2032.
Which Global Pain Therapeutics Market segment held the largest share in 2024?
In 2024, the opioid analgesics segment held the largest share of 41%, driven by widespread adoption in managing severe chronic pain and oncology-related pain conditions.
What are the primary factors fueling the growth of the Global Pain Therapeutics Market?
Key growth drivers include the rising prevalence of chronic pain disorders, expansion of non-opioid drugs, advances in personalized medicine, and increasing healthcare investments worldwide.
Who are the leading companies in the Global Pain Therapeutics Market?
Leading companies include Abbott, Pfizer, AstraZeneca, Eli Lilly, GSK, Merck & Co., Sanofi, Bristol-Myers Squibb, Boston Scientific, and Purdue Pharma, along with emerging regional players.
Which region commanded the largest share of the Global Pain Therapeutics Market in 2024?
In 2024, the Asia Pacific region commanded the largest market share of 35.9%, supported by rising healthcare expenditure, large patient pool, and strong demand for therapies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
U.S. Compounding Pharmacies market size was valued at USD 3,293.81 Million in 2018, rising to USD 4,743.43 Million in 2024, and is anticipated to reach USD 7,651.56 Million by 2032, growing at a CAGR of 5.73% during the forecast period.
The UK Compounding Pharmacies market was valued at USD 173.65 million in 2018 and grew to USD 237.16 million in 2024. The market is projected to reach USD 354.16 million by 2032, registering a CAGR of 4.79% during the forecast period.
The North America Compounding Pharmacies Market size was valued at USD 3,956.45 million in 2018 and increased to USD 5,674.29 million in 2024. It is anticipated to reach USD 9,265.27 million by 2032, registering a CAGR of 5.89% during the forecast period.
Dermatology Drugs Market size was valued USD 29.7 billion in 2024 and is anticipated to reach USD 63.2 billion by 2032, at a CAGR of 9.9% during the forecast period.
Australia Pharmaceutical Water Market size was valued at USD 389.54 million in 2018, grew to USD 779.59 million in 2024, and is anticipated to reach USD 1,736.49 million by 2032, expanding at a CAGR of 9.81% during the forecast period.
The Europe Pharmaceutical Water Market was valued at USD 4,290.41 million in 2018, grew to USD 7,235.40 million in 2024, and is anticipated to reach USD 14,105.75 million by 2032, expanding at a CAGR of 8.0% during the forecast period.
The North America Pharmaceutical Water Market was valued at USD 9,849.30 million in 2018, grew to USD 17,393.16 million in 2024, and is projected to reach USD 37,427.29 million by 2032, expanding at a CAGR of 9.4% during the forecast period.
Global Pharmaceutical Water Market size was valued at USD 23,162.04 million in 2018, grew to USD 41,343.44 million in 2024, and is anticipated to reach USD 88,711.39 million by 2032, expanding at a CAGR of 9.33% during the forecast period.
Japan Pharmaceutical Water Market size was valued at USD 819.04 million in 2018, grew to USD 1,672.74 million in 2024, and is anticipated to reach USD 3,843.83 million by 2032, expanding at a CAGR of 10.21% during the forecast period.
The UK Pharmaceutical Water Market was valued at USD 299.29 million in 2018, increased to USD 550.93 million in 2024, and is projected to reach USD 1,087.93 million by 2032, expanding at a CAGR of 8.27% during the forecast period.
The U.S. Pharmaceutical Water Market was valued at USD 5,673.65 million in 2018, increased to USD 11,018.40 million in 2024, and is projected to reach USD 23,471.03 million by 2032, expanding at a CAGR of 9.23% during the forecast period.
The Italy Pharmaceutical Water Market was valued at USD 460.92 million in 2018, grew to USD 817.32 million in 2024, and is projected to reach USD 1,534.50 million by 2032, expanding at a CAGR of 7.63% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
